Examine goals to construct a complete, open-source database of heritable genetics and patient-reported information in lung most cancers
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a number one genetic well being and biopharmaceutical firm, in collaboration with 20 lung most cancers advocacy organizations, at present introduced a brand new examine to assist advance analysis in lung most cancers. The main focus of the Lung Most cancers Genetics Examine is to higher perceive the genetics of individuals with lung most cancers as a way to enhance detection, threat discount, and care. Whereas latest developments in tumor genetic testing and focused therapies have offered hope and years of survival to many lung most cancers sufferers, lung most cancers stays the primary explanation for most cancers deaths in each women and men in the USA. But, a lot stays unknown concerning the illness and its causes.
“There’s a nice want to higher outline the underlying genetics of lung most cancers,” stated Courtney Granville, Chief Scientific Officer at GO2 for Lung Most cancers. “We’re privileged to face along with the analysis and affected person advocacy communities to contribute to this effort to higher outline inherited threat for lung most cancers and inform our potential to stop, diagnose, and deal with individuals. In the end, the learnings from this examine will enhance outcomes for future generations.”
The de-identified information from the examine might be made obtainable to accepted researchers, and entry to the scientific database might be obtainable to nonprofit researchers and establishments for gratis.
Sobering lung most cancers statistics solely inform a part of the story
Regardless of advances in therapy choices, lung most cancers stays a essential space of unmet want:
-
In 2020, lung most cancers took extra lives in the USA than breast, colorectal, and prostate cancers mixed.
-
One in 16 individuals in the USA might be recognized with lung most cancers of their lifetime.
-
It’s estimated that in 2024, 234,000 new individuals might be recognized with lung most cancers in the USA.
-
Whereas lung most cancers accounts for 12% of all new most cancers diagnoses, it accounts for 20% of most cancers deaths.
-
Regardless of being the deadliest most cancers, lung most cancers analysis is underfunded in comparison with different most cancers varieties.
-
Early detection of lung most cancers via screening can dramatically enhance the long-term survival fee. Solely 25% of all individuals recognized with lung most cancers will survive 5 years or extra, however for these whose most cancers was recognized via annual screening by CT scan, the 20-year survival fee is 81%.
-
In individuals recognized at 55 years of age or youthful, lung most cancers is extra widespread in ladies than males. Amongst individuals with lung most cancers who’ve by no means smoked, roughly two-thirds are ladies, making ladies who haven’t smoked greater than twice as more likely to develop lung most cancers as males who haven’t smoked.
Behind each devastating statistic are individuals from communities throughout the U.S. impacted by lung most cancers. By means of this collaboration, advocacy organizations, lung most cancers survivors and advocates, and 23andMe hope in the end to assist advance analysis towards discovering a remedy for this illness.
“LUNGevity Basis is happy to associate on this community-driven challenge,” stated Upal Basu Roy, Vice President of Analysis at LUNGevity Basis. “As a researcher and a affected person advocate, I am most enthusiastic about how the info collected on this examine may very well be leveraged to assist sufferers sooner or later. For instance, it may assist researchers determine new drug targets and mechanisms for drug growth or discover methods to handle negative effects proactively.”
This examine contains the next collaborators: ALK Constructive, Biomarker Collaborative, BRAF Bombers, EGFR Resisters, Exon 20 Group, Free ME from Lung Most cancers, GO2 for Lung Most cancers, The Comfortable Lungs Challenge, Worldwide Most cancers Advocacy Community, KRAS Kickers, Lung Most cancers Basis of America, Lung Most cancers Analysis Basis, LUNGevity Basis, MET Crusaders, NTRKers, Oncogene Most cancers Analysis, PDL1 Amplifieds, RET Constructive, RET Renegades, The ROS1ders, and Troper Wojcicki Philanthropies.
“Learning the genetics of lung most cancers will help us perceive dangers, enhance early detection, and develop higher remedies. This collaborative effort unites sufferers, advocates, docs, and researchers,” stated Jill Feldman, affected person advocate and co-founder of the EGFR Resisters. “By making the info securely accessible to researchers worldwide, the Lung Most cancers Genetics Examine will increase our possibilities of breakthroughs that may save lives.”
Enhancing lung most cancers analysis
The 23andMe analysis platform will allow consented individuals to return collectively to offer essential information for scientists finding out lung most cancers. Analysis information will embody genetic info and self-reported details about every participant’s distinctive experiences (utilizing responses from on-line surveys), in addition to further information sources comparable to medical information and tumor biomarker info. By means of this examine, advocacy organizations, advocates, and 23andMe goal to boost analysis into lung most cancers by bringing collectively a big group of individuals to higher perceive how genetics could affect lung most cancers, increasing the geographic attain of the analysis examine by enabling participation from house, and eradicating a number of the time and price limitations that may gradual progress.
How this examine will help additional analysis
The aim of the examine is to recruit 10,000 individuals who have been recognized with lung most cancers, with no restrictions on the kind of lung most cancers, stage of illness, gender, smoking standing, biomarker, or different variables. The lung most cancers genetics examine is recruiting people who’re 18 years or older, dwell in the USA, and have been recognized with lung most cancers. Members within the examine can obtain the 23andMe kits for gratis.
“By means of the launch of the Lung Most cancers Genetics Examine, we hope to fill an unmet want for a complete database that bridges the hole between genetic, scientific, and patient-reported information,” stated Anne Wojcicki, Co-Founder and CEO of 23andMe. “As a result of lung most cancers impacts individuals from all communities, it is vital for this analysis to really replicate the variety of these impacted by the illness. This collaborative effort unites survivors, caregivers, researchers, and advocates who’re all devoted to enhancing the therapy and care of lung most cancers.”
The Lung Most cancers Genetics Examine is made attainable by help from Troper Wojcicki Philanthropies (TWP). Troper Wojcicki Philanthropies deploys philanthropy and mission-related investments to organizations which are accelerating most cancers analysis, tackling local weather change, and advancing human rights. Since 2006, TWP has dedicated greater than $100M to researchers, teachers, and entrepreneurs dedicated to creating a optimistic impression on the world. For the final 15 years, 30% of TWP’s funding has been devoted to advancing most cancers analysis.
For extra info on the examine, please see the Lung Most cancers Genetics Examine touchdown web page.
About 23andMe
23andMe is a genetics-led shopper healthcare and biopharmaceutical firm empowering a more healthy future. For extra info, please go to www.23andMe.com.
Ahead-Wanting Statements
This press launch accommodates forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, together with. All statements, apart from statements of historic truth, included or integrated on this press launch are forward-looking statements. The phrases “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “could,” “may,” “ought to,” “potential,” “seemingly,” “tasks,” “predicts,” “proceed,” “will,” “schedule,” and “would” or, in every case, their detrimental or different variations or comparable terminology, are meant to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. These forward-looking statements are predictions primarily based on 23andMe’s present expectations and projections about future occasions and numerous assumptions. 23andMe can’t assure that it’s going to really obtain the plans, intentions, or expectations disclosed in its forward-looking statements and you shouldn’t place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements contain quite a lot of dangers, uncertainties (a lot of that are past the management of 23andMe), or different assumptions that will trigger precise outcomes or efficiency to vary materially from these expressed or implied by these forward-looking statements. The forward-looking statements contained herein are additionally topic typically to different dangers and uncertainties which are described once in a while within the Firm’s filings with the Securities and Alternate Fee, together with underneath Merchandise 1A, “Danger Components” within the Firm’s most up-to-date Annual Report on Kind 10-Ok, as filed with the Securities and Alternate Fee, and as revised and up to date by our Quarterly Stories on Kind 10-Q and Present Stories on Kind 8-Ok. The statements made herein are made as of the date of this press launch and, besides as could also be required by regulation, 23andMe undertakes no obligation to replace them, whether or not on account of new info, developments, or in any other case.
Contacts
Media: press@23andMe.com
Investor Relations: traders@23andMe.com